Suvretta Capital Management LLC Increases Position in Mineralys Therapeutics, Inc. $MLYS

Suvretta Capital Management LLC raised its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 22.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,132,133 shares of the company’s stock after acquiring an additional 387,641 shares during the period. Mineralys Therapeutics makes up approximately 2.1% of Suvretta Capital Management LLC’s investment portfolio, making the stock its 12th largest position. Suvretta Capital Management LLC’s holdings in Mineralys Therapeutics were worth $80,850,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of MLYS. Orbimed Advisors LLC purchased a new stake in shares of Mineralys Therapeutics in the second quarter valued at approximately $10,288,000. Stempoint Capital LP increased its holdings in shares of Mineralys Therapeutics by 605.3% in the second quarter. Stempoint Capital LP now owns 631,586 shares of the company’s stock valued at $8,551,000 after purchasing an additional 756,586 shares during the last quarter. Vanguard Group Inc. lifted its position in Mineralys Therapeutics by 29.8% during the third quarter. Vanguard Group Inc. now owns 3,018,999 shares of the company’s stock worth $114,480,000 after buying an additional 692,550 shares in the last quarter. Wellington Management Group LLP boosted its stake in Mineralys Therapeutics by 578.6% during the third quarter. Wellington Management Group LLP now owns 783,445 shares of the company’s stock worth $29,708,000 after buying an additional 667,997 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Mineralys Therapeutics by 15,142.2% during the third quarter. BNP Paribas Financial Markets now owns 626,148 shares of the company’s stock worth $23,744,000 after buying an additional 622,040 shares during the last quarter. 84.46% of the stock is owned by hedge funds and other institutional investors.

Mineralys Therapeutics Stock Performance

Shares of Mineralys Therapeutics stock opened at $26.19 on Friday. The stock has a 50 day moving average of $30.45 and a 200 day moving average of $35.37. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -11.05 and a beta of 0.57. Mineralys Therapeutics, Inc. has a fifty-two week low of $10.44 and a fifty-two week high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17. Analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on MLYS. Stifel Nicolaus upped their target price on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, December 19th. Bank of America boosted their price target on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research report on Friday. HC Wainwright set a $56.00 price objective on shares of Mineralys Therapeutics and gave the company a “buy” rating in a report on Tuesday. Jefferies Financial Group restated a “hold” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Friday. Finally, Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.14.

Mineralys Therapeutics News Roundup

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: NDA accepted by FDA and PDUFA set (Dec. 22, 2026) for lorundrostat — formal regulatory review underway, which de-risks timing for potential approval and commercialization. GlobeNewswire: Q4 results & NDA acceptance
• Positive Sentiment: Q4 results surprised to the upside — reported EPS of ($0.40) vs. consensus ($0.57), suggesting operational execution beat expectations and reducing near-term downside to estimates. MarketBeat: Q4 earnings summary
• Positive Sentiment: Management is actively preparing for launch and payer engagement ahead of the regulatory decision — signaling commercialization planning and market-access work that could speed uptake if approved. Seeking Alpha: Launch & payer engagement
• Neutral Sentiment: Conference call and transcript provide management’s roadmap and data context (Q4 call reviewed NDA strategy, clinical data and next steps); useful for modeling but not a surprise item. Seeking Alpha: Earnings call transcript
• Neutral Sentiment: Press coverage highlights steady progress with FDA interactions and public messaging; these articles reiterate facts rather than deliver new catalysts. Yahoo Finance: FDA progress TipRanks: NDA acceptance overview
• Negative Sentiment: Critical commentary warns of potential interference from larger pharma interests that could complicate the approval or market dynamics — introduces regulatory and competitive risk that can pressure shares. Seeking Alpha: Concerns over big pharma pressure

Insider Buying and Selling

In related news, CEO Jon Congleton sold 16,236 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.62, for a total value of $529,618.32. Following the sale, the chief executive officer directly owned 639,151 shares in the company, valued at approximately $20,849,105.62. The trade was a 2.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Adam Scott Levy sold 10,758 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.14, for a total transaction of $345,762.12. Following the completion of the transaction, the chief financial officer directly owned 8,638 shares in the company, valued at $277,625.32. The trade was a 55.47% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 342,919 shares of company stock valued at $11,755,439. 25.56% of the stock is currently owned by insiders.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.